Challenges in the Commercialization of Array-Based Tests

  • Justin Petrone


Since the advent of array-based molecular diagnostics early in the last decade, the tests have faced a number of challenges, including an evolving regulatory environment, costs associated with developing a test and bringing it through a regulatory clearance process, costs associated with the technology itself, both the assay kits and the underlying platforms, hesitance from insurers to reimburse tests, questions about the clinical utility of the new assays, community awareness of the tests’ benefits, and competition from other technology platforms. While there are many obstacles to achieving success, array-based tests used in constitutional cytogenetics have been widely adopted and are now considered the standard of care. Revenues for other tests continue to grow, though not in line with earlier predictions. This chapter examines the challenges associated with bringing an array-based test to market and how they have been overcome.


Initial Public Offering Molecular Diagnostics Genomic Health Affymetrix Platform Regulatory Clearance 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Affymetrix (2011) Current powered by Affymetrix partners.
  2. Agendia (2011a) A history of science.
  3. Agendia (2011b) Agendia prospectus.
  4. Allison M (2008) Is personalized medicine finally arriving? Nat Biotechnol 26:509–517PubMedCrossRefGoogle Scholar
  5. Autogenomics (2011) AutoGenomics molecular diagnostics products.
  6. Baker L et al (2010) p53 mutation, deprivation and poor prognosis in primary breast cancer. Br J Cancer 102(4):719–26PubMedCrossRefGoogle Scholar
  7. Chiaretti S et al (2011) Evaluation of TP53 mutations with the AmpliChip p53 research test in chronic lymphocytic leukemia: correlation with clinical outcome and gene expression profiling. Genes Chromosomes Cancer 50(4):263–74PubMedGoogle Scholar
  8. College of American Pathologists (2010) In vitro diagnostic multivariate index assays.{actionForm.contentReference}=committees%2Ftechnology%2Fivdmia.html&_state=maximized&_pageLabel=cntvwrGoogle Scholar
  9. CombiMatrix (2011a) CombiMatrix receives New York State Clinical Laboratory Permit.
  10. CombiMatrix (2011b) Combimatrix Corporation reports second quarter 2011 financial results.
  11. Dumur C et al (2008) Interlaboratory performance of a microarray-based gene expression test to determine tissue of origin in poorly differentiated and undifferentiated cancers. J Mol Diagn 10(1):67–77PubMedCrossRefGoogle Scholar
  12. Dunbar L (2009) Clinician experiences of employing the AmpliChip(R) CYP450 test in routine psychiatric practice. J Psychopharmacol. doi: 10.1177/0269881109106957
  13. GenMark Diagnostics (2011) GenMark diagnostics reports second quarter 2011 results.
  14. Genomic Health (2011a) The OncoType Dx Breast Cancer Assay.
  15. Genomic Health (2011b) Genomic Health announces year-end 2010 financial results, provides 2011 financial outlook.
  16. Glück S et al (2011) TP53 genomics predict higher clinical and pathologic tumor response in operable early-stage breast cancer treated with docetaxel-capecitabine ± trastuzumab. Breast Cancer Res Treat [Epub ahead of print]Google Scholar
  17. Goldhirsch A et al (2011) Strategies for subtypes–dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 22(8):1736–47PubMedCrossRefGoogle Scholar
  18. Jordan B (2010) Is there a niche for DNA microarrays in molecular diagnostics? Expert Rev Mol Diagn 10(7):875–82PubMedCrossRefGoogle Scholar
  19. Kearney H et al (2011) American College of Medical Genetics standards and guidelines for interpretation and reporting of postnatal constitutional copy number variants. Genet Med 13(7):680–5PubMedCrossRefGoogle Scholar
  20. Krochmal M (2003) Roche’s AmpliChip Microarray faces regulatory hurdles for Tech and Tests.BioArray News.
  21. Li X et al (2008) Clinical utility of microarrays: current status, existing challenges and future outlook. Curr Genomics 9(7):466–74PubMedCrossRefGoogle Scholar
  22. Manning M et al (2010) Array-based technology and recommendations for utilization in medical genetics practice for detection of chromosomal abnormalities. Genet Med 12(11):742–5PubMedCrossRefGoogle Scholar
  23. Petrone J (2009a) FDA may increase oversight over array-based clinical cytogenetic tests. BioArray News.
  24. Petrone J (2009b). Signature genomic labs to solely offer array CGH services on Roche NimbleGen Platform. BioArray News.
  25. Petrone J (2010a) CGC genetics adopts Illumina BeadXpress for clinical genetic testing. BioArray News.
  26. Petrone J (2010b) Merck to use Roche’s p53 AmpliChip for cancer research. BioArray News.
  27. Petrone J (2010c) FDA clears pathwork diagnostics’ tissue-of-origin test for use with FFPE samples. BioArray News.
  28. Petrone J (2010d) PerkinElmer to acquire Cyto Array firm signature genomic labs for $90 M to Bolster Testing Services. BioArray News.
  29. Petrone J (2010e) FDA, labs, vendors take steps toward regulatory ground rules for array-based cytogenetic testing. BioArray News.
  30. Petrone J (2011a) Skyline Diagnostics Preps Leukemia test for US launch; gains CE-IVD Mark. BioArray News.
  31. Petrone J (2011b). Despite years of development, Affymetrix’s Dx partners slow to bring tests to market.
  32. Petrone J (2011c) BioMerieux to move array-based tests to Biocartis, other MDx platforms. BioArray News.
  33. Petrone J (2011d) CombiMatrix to introduce gene-mutation testing; Q2 revenues Climb 31 percent. BioArray News.
  34. Petrone J (2011e) Validation and reproducibility of a microarray-based gene expression test for tumor identification in formalin-fixed, paraffin-embedded specimens. J Mol Diagn 13(1):48–56CrossRefGoogle Scholar
  35. Pillai R et al (2011) Validation and reproducibility of a microarray-based gene expression test for tumor identification in formalin-fixed, paraffin-embedded specimens. J Mol Diagn 13(1):48–56PubMedCrossRefGoogle Scholar
  36. Schaaf C et al (2011) Copy number and SNP arrays in clinical diagnostics. Annu Rev Genomics Hum Genet 12:25–51 (Review)Google Scholar
  37. Shapiro J, Prebula R (2003) FDA’s regulation of analyte-specific reagents. Medical Device and Diagnostic Industry.
  38. SQI Diagnostics (2011) SQI Diagnostics reports third quarter financial results.
  39. Winnick E (2004a) Roche and Affy win EU approval for AmpliChip, Microarray Dx Platform.
  40. Winnick E (2004b) Affymetrix, Roche file for US clearance of microarray-based diagnostic products. BioArray News.

Copyright information

© Springer-Verlag Berlin Heidelberg 2012

Authors and Affiliations

  1. 1.BioArray News, GenomeWeb LLCNew YorkUSA

Personalised recommendations